TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23975354

Group type: EXPERIMENTAL
Intervention: Acute treatment for adolescent depression for 12 weeks followed by an additional 12 weeks of treatment.
Number of subjects: 334
Study: 22180621

Group type: EXPERIMENTAL
Intervention: Immediate treatment (IT) - 36 weeks of antiretrovirals
Number of subjects: 130

Group type: COMPARATOR
Intervention: Deferred treatment (DT) - no treatment initially
Number of subjects: 130
Study: 20209126

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone (CD)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1280
Study: 17696268

Group type: EXPERIMENTAL
Intervention: Computer tool designed to elicit preferences based on patient tradeoffs for treatment options.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Information pamphlet
Number of subjects: 87
Study: 15870044

Group type: EXPERIMENTAL
Intervention: Coronary bypass plus mitral valve repair (group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Coronary bypass alone (group B)
Number of subjects: 38
Study: 11960953

Group type: EXPERIMENTAL
Intervention: ACh infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tyramine infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 9
Study: 9858440

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once a day for 14 days
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once a day for 28 days
Number of subjects: 1905
Study: 8582220

Group type: EXPERIMENTAL
Intervention: Naloxone (0.02mg/kg) and normal saline (200ml)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline (200ml)
Number of subjects: 21
Study: 2121490

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Tissue plasminogen activator (tPA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 240
Study: 43255

Group type: EXPERIMENTAL
Intervention: Penbutolol (0.08 mg/kg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprenolol (0.4 mg/kg i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol (0.4 mg/kg i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol (160 mg b.i.d. orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprenolol (400 mg b.i.d. orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg b.i.d. orally)
Number of subjects: 6
Study: 31481375

Group type: EXPERIMENTAL
Intervention: s-ketamine (0.25 mg/kg bolus followed by 0.1 mg/kg/hour continuous infusion)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 62
Study: 28291960

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with ologen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 20
Study: 25679340

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 15 min) followed by 45 min physical therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study: 23846792

Group type: EXPERIMENTAL
Intervention: Excessive sleep (≥ 9 hours per 24-hour period)
Number of subjects: 19136

Group type: EXPERIMENTAL
Intervention: Excessive quantity of sleep (EQS) with distress/impairment
Number of subjects: 19136

Group type: COMPARATOR
Intervention: Individuals with mood disorder
Number of subjects: 19136

Group type: EXPERIMENTAL
Intervention: EQS individuals
Number of subjects: 19136

Group type: EXPERIMENTAL
Intervention: Individuals with prolonged sleep
Number of subjects: 19136
Study: 21851353

Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse (containing CPPs) applied to the right-sided specimen for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mousse applied to the left-sided specimen for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group B) with two enamel specimens placed into the mouth
Number of subjects: 40
Study: 19433434

Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Therapeutic gloves
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nutritional supplements
Number of subjects: 20
Study: 17705695

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day) as add-on therapy to metformin or SU
Number of subjects: 250

Group type: COMPARATOR
Intervention: Fixed-dose combination of metformin (400 mg) and glibenclamide (2.5 mg)
Number of subjects: 250
Study: 14762242

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 222

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 12-step facilitation
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 11245756

Group type: EXPERIMENTAL
Intervention: Experimental group executed a maximal isometric elbow flexion contraction immediately before a maximal elbow extension contraction.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group performed maximal isometric contractions of the elbow extensors.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups performed 5 cycles of a 2‐second contraction with 22‐second rest periods between agonist muscle contractions.
Number of subjects: 26
Study: 10660974

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg t.i.d. (n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 25
Study: 7887022

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (4 doses, 4.1 x 10(8) to 1.1 x 10(9) c.f.u.)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 2905245

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 29758078

Group type: EXPERIMENTAL
Intervention: Provision of written information about electrodiagnostic testing
Number of subjects: 128
Study: 26787797

Group type: EXPERIMENTAL
Intervention: Dexketoprofen/tramadol 25 mg/75 mg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Dexketoprofen 25 mg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 25619263

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 202
Study: 23421535

Group type: EXPERIMENTAL
Intervention: AF ablation + renal sympathetic denervation (RSDN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AF ablation alone (control group)
Number of subjects: 0
Study: 21905942

Group type: EXPERIMENTAL
Intervention: FlexTouch® (FT)
Number of subjects: 120
Study: 18573718

Group type: EXPERIMENTAL
Intervention: 3.5 mM TauBr cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% Clindamycin gel (Clindacin T)
Number of subjects: 40
Study: 17312341

Group type: EXPERIMENTAL
Intervention: Older UVH
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Older CON
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Older UVH and Older CON
Number of subjects: 31

Group type: COMPARATOR
Intervention: Young CON
Number of subjects: 31
Study: 14716362

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study: 10731011

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g x kg(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NaCl (0.21 g x kg(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo Control (PC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NaCl
Number of subjects: 8

Group type: COMPARATOR
Intervention: PC
Number of subjects: 8
Study: 9193187

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portasystemic shunt (TIPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Small-diameter prosthetic H-graft portacaval shunt (HGPCS)
Number of subjects: 40
Study: 1382132

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three antihistamines (Cetirizine, Promethazine, Chlorpheniramine)
Number of subjects: 0
Study: 3515919

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg orally twice a day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sulindac (150 mg orally twice a day)
Number of subjects: 143
Study: 29915914

Group type: EXPERIMENTAL
Intervention: Regular aspirin use
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control (non-users of aspirin)
Number of subjects: 403
Study: 26663880

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg, then 150 mg d(-1)) plus Aspirin (100 mg d(-1))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clopidogrel plus Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg) plus Aspirin (300 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ticagrelor plus Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus Aspirin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 44
Study: 23989971

Group type: EXPERIMENTAL
Intervention: Polidocanol+Laser
Number of subjects: 517

Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 517
Study: 22542489

Group type: EXPERIMENTAL
Intervention: Endurance training (ETr; n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Coordination training (CTr; n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active mobility training (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 20706107

Group type: EXPERIMENTAL
Intervention: Human papillomavirus DNA testing
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid
Number of subjects: 956

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 956
Study: 18971491

Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 1974
Study: 15942159

Group type: EXPERIMENTAL
Intervention: Oat bran supplement (2 oat bran-enriched muffins per day, 28 g/day of oat bran)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oat bran supplement
Number of subjects: 34
Study: 11936532

Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost (15 microg)
Number of subjects: 10
Study: 10464004

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl‐trinitrate (24 h/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl‐trinitrate (16 h/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 36
Study: 7628025

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rectal thiopentone 35 mg.kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 75
Study: 2127268

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil, 5-day treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin, 10-day treatment
Number of subjects: 0
Study: 7208257

Group type: EXPERIMENTAL
Intervention: Stimulus intensity at 40, 55, and 70 dB SPL with varying SOA (0, 1, 2, and 4 to 28 msec in 4-msec steps)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulus intensity and SOA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulus intensity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensity by SOA by Task interaction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temporal order task
Number of subjects: 20
Study: 31046014

Group type: EXPERIMENTAL
Intervention: Online eye drop technique educational video
Number of subjects: 43
Study: 28132059

Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-Braun anastomosis
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: DGE presence
Number of subjects: 68
Study: 26275480

Group type: EXPERIMENTAL
Intervention: PCV13 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPV23 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunosuppressive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF‐α treatment
Number of subjects: 0
Study: 23600452

Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-VBN-assisted group
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for right upper lobe lesions
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-VBN-assisted group for right upper lobe lesions
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for lesions invisible on posterior-anterior radiographs
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-VBN-assisted group for lesions invisible on posterior-anterior radiographs
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for lesions in the peripheral third of the lung field
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-VBN-assisted group for lesions in the peripheral third of the lung field
Number of subjects: 350
Study: 21844413

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for acute rhinosinusitis
Number of subjects: 166
Study: 19828373

Group type: EXPERIMENTAL
Intervention: HRQoL assessment using EORTC QLQ-C30
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Fatigue assessment using Multidimensional Fatigue Inventory (MFI-20)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Fatigue at the end of treatment as a predictive variable for persistent fatigue
Number of subjects: 935
Study: 16768837

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 25-30 g/d
Number of subjects: 11

Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 11
Study: 15606633

Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard interferon plus ribavirin
Number of subjects: 21
Study: 11642626

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines (HbOC or Hib-OMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PnPs)
Number of subjects: 0
Study: 9539303

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) at a dose of 0.5-1.5 mg/week (n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bromocriptine (BRC) at a dose of 5-15 mg/day (n = 10)
Number of subjects: 17
Study: 7859174

Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride (50 micrograms/kg)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Droperidol (50 micrograms/kg)
Number of subjects: 393
Study: 2816802

Group type: EXPERIMENTAL
Intervention: 30 mg zinc (gluconate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1234492

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 12
Study: 30665869

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 28923219

Group type: EXPERIMENTAL
Intervention: Surgical management of gastrointestinal stromal tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical management of gastrointestinal stromal tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance based on studies
Number of subjects: 0
Study: 26329410

Group type: EXPERIMENTAL
Intervention: Cover wound dressing (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No cover dressing (n = 20)
Number of subjects: 40
Study: 23851398

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22159849

Group type: EXPERIMENTAL
Intervention: ORIF with a volar locking plate (n = 36)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Closed reduction and plaster immobilization (n = 37)
Number of subjects: 73
Study: 19015347

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of body weight weekly (arm A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 mg/kg loading dose followed by 6 mg/kg every 2 weeks (arm B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 25 mg/kg every 2 weeks for five doses (arm C)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibalizumab (all arms)
Number of subjects: 22
Study: 16785153

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH‐ant)
Number of subjects: 60
Study: 14963375

Group type: EXPERIMENTAL
Intervention: Visual feedback-based balance training (exercise group, n = 20)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 27
Study: 11404520

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (DP)
Number of subjects: 244
Study: 9423751

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 200 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 600 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (Premarin 0.625 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8423538

Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.32 mg/70 kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: d‐Amphetamine (5 and 20 mg/70 kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Novel-response procedure
Number of subjects: 4

Group type: COMPARATOR
Intervention: Two-response procedure
Number of subjects: 4
Study: 3310771

Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 30519807

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 700

Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 700
Study: 28368869

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy administered in 12 one-hour sessions over a 1-month period.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group measured on the Subjective Units of Distress Scale and a pain-rating scale at initial session, 1-month, and 24-month follow-up.
Number of subjects: 60
Study: 25344589

Group type: EXPERIMENTAL
Intervention: Low salicylate diet (LS)
Number of subjects: 10
Study: 23821089

Group type: EXPERIMENTAL
Intervention: Home-based group-mediated cognitive behavioral walking intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 194
Study: 21858735

Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 19
Study: 18295282

Group type: EXPERIMENTAL
Intervention: Buccal mucosa grafts
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acellular bladder matrix grafts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Buccal mucosa and Acellular bladder matrix)
Number of subjects: 30
Study: 16802767

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg daily)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 360
Study: 14503438

Group type: EXPERIMENTAL
Intervention: Sensory training for 4 weeks followed by motor training for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Motor training for 4 weeks followed by sensory training for 4 weeks
Number of subjects: 21
Study: 10817717

Group type: EXPERIMENTAL
Intervention: Oral dOTC (800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous dOTC (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (+) dOTC
Number of subjects: 12
Study: 8751401

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) consisting of intracavitary brachytherapy alone to a median dose of 21 Gy for 17 patients.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) consisting of external beam RT to a median dose of 45 Gy followed by intracavitary brachytherapy to a median dose of 12 Gy for 81 patients.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 98
Study: 2059396

Group type: EXPERIMENTAL
Intervention: nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 394

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 394
Study: 6137427

Group type: EXPERIMENTAL
Intervention: Solpadeine (paracetamol 500 mg, codeine phosphate 8 mg, caffeine 30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soluble DNP (dextropropoxyphene napsylate equivalent to 32.5 mg hydrochloride and paracetamol 325 mg)
Number of subjects: 0
Study: 31542525

Group type: EXPERIMENTAL
Intervention: Visual analysis of myocardial perfusion
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Semiquantitative analysis of myocardial perfusion
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fully quantitative analysis of myocardial perfusion
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stress myocardial blood flow analysis
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Myocardial flow reserve (MFR) analysis
Number of subjects: 77